Metis Global Partners, LLC Outlook Therapeutics, Inc. Transaction History

Metis Global Partners, LLC

  • $3.16 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023
BUY
$0.87 - $1.33 $26,696 - $40,812
30,686 Added 174.32%
48,289 $52,000
Q2 2022

Aug 08, 2022
BUY
$0.91 - $2.01 $16,018 - $35,382
17,603 New
17,603 $18,000

Others Institutions Holding OTLK

# of Institutions
3
Shares Held
31.5K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.17B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Metis Global Partners, LLC Portfolio

Follow Metis Global Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metis Global Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Metis Global Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email